CARM Carisma Therapeutics, Inc.
USHealthcareAs of 2026-07-10 15:44
Why CARM matters now
Carisma Therapeutics, Inc. (CARM) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.01 with +0.00% on the session and $230.1K in market capitalization; recent performance reads 1-month +18900.00% and YTD -55.81%.
The latest financial table shown here is Q3 2025, with revenue of $45.3M, net income of $44.7M, and EPS of $1.07. Investors can compare that operating picture with valuation signals such as P/E 0.18 and FCF yield -2819.3%.
The latest indexable market news headline is "Critical Review: Carisma Therapeutics (NASDAQ:CARM) vs. Protalex (OTCMKTS:PRTX)" from Defense World.
Additional event context on this page matters because analyst consensus is Hold with a median target of $6.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
0.18
PEG
0.00
P/B
-0.92
P/S
0.02
EV/EBITDA
-0.09
DCF Value
$-44.51
FCF Yield
-2819.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.1%
Operating Margin
20.6%
Net Margin
15.3%
ROE
-28.9%
ROA
122.7%
ROIC
-10330.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $45.3M | $44.7M | $1.07 |
| Q2 2025 | $0.00 | $-9.8M | $-0.23 |
| Q1 2025 | $3.7M | $-9.3M | $-0.22 |
| Q4 2024 | $3.7M | $-17.6M | $-0.42 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$6.00
Target (Median)
$6.00
Target Range
$6.00 - $6.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.80
Carisma Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to pioneering chimeric antigen receptor (CAR) macrophage therapies specifically designed to target solid cancerous growths. Its therapeutic approaches are instrumental in modulating both the inherent and acquired functions of the immune system. The company's sophisticated platform draws upon breakthroughs in macrophage science, CAR design, and cell-based treatments to address various human ailments. Notably, Carisma Therapeutics maintains a key strategic alliance with Moderna Inc. Incorporated in 2016 and headquartered in Philadelphia, Pennsylvania, the organization was initially established as CARMA Therapeutics Inc., before rebranding to its current name, Carisma Therapeutics, Inc., in May of 2017.